QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 akebia-therapeutics-q1-2024-gaap-eps-009-misses-008-estimate-sales-32607m-miss-46087m-estimate

Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of...

 hc-wainwright--co-maintains-buy-on-akebia-therapeutics-raises-price-target-to-6

HC Wainwright & Co. analyst Ed Arce maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and raises the price target f...

 fda-approves-for-akebia-therapeutics-vafseo-for-kidney-disease-associated-anemia

The FDA-approved Vafseo tablets by Akebia Therapeutics for managing anemia in adult dialysis patients with chronic kidney disea...

 why-rh-shares-are-trading-higher-by-around-9-here-are-20-stocks-moving-premarket

Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results.

 reported-earlier-akebias-wins-fda-approval-of-vafseo-tablets-for-dialysis-related-anemia-treatment

Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia  Akebia's Launch Strategy Developed to ...

 cintas-reports-upbeat-earnings-joins-paysign-noah-holdings-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.

 why-westport-fuel-systems-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected ...

 hc-wainwright--co-reiterates-buy-on-akebia-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $5 price target.

 akebia-therapeutics-q4-sales-56200m-beat-55393m-estimate

Akebia Therapeutics (NASDAQ:AKBA) reported quarterly sales of $56.200 million which beat the analyst consensus estimate of $55....

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.